Sarcoma  >>  lapatinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
NCT00107003: GW572016 to Treat Recurrent Malignant Brain Tumors

Completed
2
9
US
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
National Cancer Institute (NCI)
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
12/07
11/12
NCT00095940: Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Checkmark In children with refractory CNS malignancies
Jul 2013 - Jul 2013: In children with refractory CNS malignancies
Completed
2
52
US
lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, pharmacological studies, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, magnetic resonance imaging, MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging
National Cancer Institute (NCI)
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligodendroglioma
07/10
07/10

Download Options